AZURITY Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AZURITY, and what generic alternatives to AZURITY drugs are available?
AZURITY has thirty-two approved drugs.
There are eighty-six US patents protecting AZURITY drugs.
There are three hundred and forty patent family members on AZURITY drugs in forty-eight countries and forty-one supplementary protection certificates in fifteen countries.
Summary for AZURITY
| International Patents: | 340 |
| US Patents: | 86 |
| Tradenames: | 31 |
| Ingredients: | 24 |
| NDAs: | 32 |
| Patent Litigation for AZURITY: | See patent lawsuits for AZURITY |
Drugs and US Patents for AZURITY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | SOTYLIZE | sotalol hydrochloride | SOLUTION;ORAL | 205108-001 | Oct 22, 2014 | RX | Yes | Yes | 11,850,222 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-001 | Jan 30, 2019 | RX | Yes | No | 10,441,554 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Azurity | PREVDUO | glycopyrrolate; neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 216903-001 | Feb 23, 2023 | RX | Yes | Yes | 11,110,054 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Azurity | FIRVANQ KIT | vancomycin hydrochloride | FOR SOLUTION;ORAL | 208910-002 | Jan 26, 2018 | AB | RX | Yes | Yes | 10,493,028 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Azurity | XATMEP | methotrexate sodium | SOLUTION;ORAL | 208400-001 | Apr 25, 2017 | RX | Yes | Yes | 10,231,927 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Azurity | ERYPED | erythromycin ethylsuccinate | TABLET, CHEWABLE;ORAL | 050297-003 | Jul 5, 1988 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AZURITY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Azurity | EDARBI | azilsartan kamedoxomil | TABLET;ORAL | 200796-002 | Feb 25, 2011 | 5,583,141 | ⤷ Try a Trial |
| Azurity | EDARBI | azilsartan kamedoxomil | TABLET;ORAL | 200796-001 | Feb 25, 2011 | 5,958,961 | ⤷ Try a Trial |
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-004 | Jan 30, 2019 | 10,130,580 | ⤷ Try a Trial |
| Azurity | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-002 | Dec 20, 2011 | 5,583,141 | ⤷ Try a Trial |
| Azurity | GLIADEL | carmustine | IMPLANT;INTRACRANIAL | 020637-001 | Sep 23, 1996 | 5,179,189 | ⤷ Try a Trial |
| Azurity | GLIADEL | carmustine | IMPLANT;INTRACRANIAL | 020637-001 | Sep 23, 1996 | 4,757,128 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AZURITY drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 1 mg/mL | ➤ Subscribe | 2018-08-31 |
| ➤ Subscribe | Powder for Oral Solution | 1 mg/mL | ➤ Subscribe | 2016-06-21 |
International Patents for AZURITY Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3145527 | ⤷ Try a Trial |
| Spain | 2694401 | ⤷ Try a Trial |
| New Zealand | 546381 | ⤷ Try a Trial |
| Brazil | PI0507984 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2014055667 | ⤷ Try a Trial |
| Spain | 2903419 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for AZURITY Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1507558 | 12C0033 | France | ⤷ Try a Trial | PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: CH - 6167801 20110705 |
| 1718641 | CA 2012 00013 | Denmark | ⤷ Try a Trial | |
| 2119715 | 300802 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL EN CHLOORTALIDON; NATIONAL REGISTRATION NO/DATE: RVG116387 20151125; FIRST REGISTRATION: CH 6314502 20141028 |
| 0984957 | SPC/GB11/013 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| 1718641 | 12C0034 | France | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/735/001 20111207 |
| 1718641 | 132012902056823 | Italy | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL(EDARBI E IPREZIV); AUTHORISATION NUMBER(S) AND DATE(S): EDARBI: DA EU/1/11/734/001 A EU/1/11/734/011; IPREZIV: DA EU/1/11/735/001 A EU/1/11/735/011, 20111207 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
